Blue Owl Capital Holdings LP
Position in KALV — KalVista Pharmaceuticals, Inc.
CIK 1858703
New York, NY
Position in KALV
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$4,327,950
-$1,486,050 QoQ
Shares Held
215,000
-40.3% QoQ
Ownership
0.404%
of shares outstanding
% of Portfolio
1.17%
of 13F equity value
Holder Rank
#49
of 182 holders
Holding Since
Sep 2025
3 quarters on record
Common Shares in KALV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Blue Owl Capital Holdings LP holds $268,354,900 across 25 Biotechnology names. KALV ranks #16 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AKTS |
Aktis Oncology, Inc.
|
3,161,348 | $56,556,515 | |
| 2 | LRMR |
Larimar Therapeutics, Inc.
|
7,120,007 | $32,040,031 | |
| 3 | ENGN |
enGene Therapeutics Inc.
|
4,416,353 | $30,075,363 | |
| 4 | CGEM |
Cullinan Therapeutics, Inc.
|
1,909,764 | $27,137,746 | |
| 5 | MPLT |
MapLight Therapeutics, Inc.
|
1,005,929 | $20,450,536 | |
| 6 | CMPX |
Compass Therapeutics, Inc.
|
2,941,525 | $15,560,667 | |
| 7 | CNTX |
Context Therapeutics Inc.
|
5,089,015 | $13,333,219 | |
| 8 | EYPT |
EyePoint, Inc.
|
912,594 | $11,763,336 |
All Filings in KALV
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,327,950 | 215,000 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $5,814,000 | 360,000 | Shares | Defined | 2026-02-20 | |
| 2025-09-30 | $1,522,500 | 125,000 | Shares | Defined | 2025-11-12 | |
| No filing history on record for this holder in this stock. | ||||||